Your browser doesn't support javascript.
loading
Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
Blomberg, Carl; Nilsson, Jonas; Holgersson, Georg; Edlund, Per; Bergqvist, Michael; Adwall, Linda; Ekman, Simon; Brattström, Daniel; Bergström, Stefan.
Afiliação
  • Blomberg C; Department of Oncology, Gävle Hospital, Gävle, Sweden Centre for Research and Development Uppsala University/County Council of Gävleborg, Uppsala, Sweden Department of Radiation Sciences and Oncology, Umeå University Hospital, Umeå, Sweden.
  • Nilsson J; Department of Oncology, Gävle Hospital, Gävle, Sweden Centre for Research and Development Uppsala University/County Council of Gävleborg, Uppsala, Sweden Department of Radiation Sciences and Oncology, Umeå University Hospital, Umeå, Sweden.
  • Holgersson G; Department of Oncology, Gävle Hospital, Gävle, Sweden Centre for Research and Development Uppsala University/County Council of Gävleborg, Uppsala, Sweden Department of Radiology, Oncology and Radiation Sciences, Uppsala University Hospital, Uppsala, Sweden.
  • Edlund P; Department of Oncology, Gävle Hospital, Gävle, Sweden.
  • Bergqvist M; Department of Oncology, Gävle Hospital, Gävle, Sweden Centre for Research and Development Uppsala University/County Council of Gävleborg, Uppsala, Sweden Department of Radiation Sciences and Oncology, Umeå University Hospital, Umeå, Sweden.
  • Adwall L; Department of Surgery, Uppsala University Hospital, Uppsala, Sweden.
  • Ekman S; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
  • Brattström D; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
  • Bergström S; Department of Oncology, Gävle Hospital, Gävle, Sweden Department of Oncology, Uppsala University Hospital, Uppsala, Sweden Department of Radiation Sciences and Oncology, Umeå University Hospital, Umeå, Sweden stefan.bergstrom@regiongavleborg.se.
Anticancer Res ; 35(5): 2493-501, 2015 May.
Article em En | MEDLINE | ID: mdl-25964522
ABSTRACT
Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy mainly localized to the pleura. Malignant mesothelioma grows highly invasive into surrounding tissue and has a low tendency to metastasize. The median overall survival (OS) of locally advanced or metastatic disease without treatment is 4-13 months but, during recent years, improvement in survival has been achieved since treatment for patients with mesothelioma has improved with better palliative care, systemic medical treatment, surgery and improved diagnostics methods. The present review aims at describing available data from randomized trials considering systemic medical treatment for this patient category.
Assuntos
Palavras-chave
Buscar no Google
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Pulmonares / Mesotelioma Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Humans Idioma: En Revista: Anticancer Res Ano de publicação: 2015 Tipo de documento: Article
Buscar no Google
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Pulmonares / Mesotelioma Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Humans Idioma: En Revista: Anticancer Res Ano de publicação: 2015 Tipo de documento: Article